Stocktoria
ADMA BIOLOGICS, INC. ADMA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2013-10-17
ADMA BIOLOGICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M | $80.9M |
| Gross profit | $292.8M | $219.6M | $88.9M | $35.3M | $1.2M |
| R&D expense | $4.8M | $1.8M | $3.3M | $3.6M | $3.6M |
| SG&A expense | $91.6M | $74.1M | $59.0M | $52.5M | $42.9M |
| Operating income | $191.4M | $139.0M | $21.6M | -$39.4M | -$58.4M |
| Interest expense | — | — | $25.0M | $19.3M | $13.1M |
| Income tax | $35.7M | -$72.0M | $0 | $0 | $0 |
| Net income | $146.9M | $197.7M | -$28.2M | -$65.9M | -$71.6M |
| EPS (diluted) | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 |
| Operating cash flow | $50.4M | $118.7M | $8.8M | -$59.5M | -$112.4M |
| Free cash flow | $27.8M | $110.4M | $4.0M | -$73.4M | -$125.9M |
| Cash & equivalents | $87.6M | $103.1M | $51.4M | $86.5M | $51.1M |
| Inventory | $206.5M | $170.2M | $172.9M | $163.3M | $124.7M |
| Total assets | $624.2M | $488.7M | $329.2M | $348.5M | $276.3M |
| Total liabilities | $146.9M | $139.7M | $194.0M | $196.5M | $135.1M |
| Shareholders' equity | $477.3M | $349.0M | $135.2M | $152.0M | $141.2M |
Source: SEC EDGAR filings · CIK 0001368514 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.